Antinuclear antibody (ANA) testing in patients treated with biological DMARDs: is it useful?

about

Antinuclear antibody (ANA) testing in patients treated with biological DMARDs: is it useful?

Item

http://www.wikidata.org/entity/Q38411852

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Antinuclear antibody (ANA) tes ...... ological DMARDs: is it useful?

@en

type

Item

label

Antinuclear antibody (ANA) tes ...... ological DMARDs: is it useful?

@en

prefLabel

Antinuclear antibody (ANA) tes ...... ological DMARDs: is it useful?

@en

P1476

Antinuclear antibody (ANA) tes ...... ological DMARDs: is it useful?

@en

P2093

Ignacio García-De LaTorre

http://www.w3.org/2001/XMLSchema#string

Ignacio García-Valladares

http://www.w3.org/2001/XMLSchema#string

P2860

Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study

Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment

Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey

A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

Role of cytokines in rheumatoid arthritis

What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort.

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.

P2888

s11926-015-0500-9

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11926-015-0500-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1017473620

http://www.w3.org/2001/XMLSchema#string

P698

25854488

http://www.w3.org/2001/XMLSchema#string